CiteULike  View Full Text   View/Add Comment  Download reader    
Ravi Prakash Rao,Ansima Singh,Arun K Jain,Bhartu Parsharthi Srinivasan.Journal of Biomedical Research,2011,25(6):411-417
Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats
Received:June 15, 2011  
DOI10.1016/S1674-8301(11)60054-7
Keywordstype 2 diabetes mellitus, diabetic nephropathy, peroxisome proliferator activated receptors (PPARs), transforming growth factor-1 (TGF-1), tumor necrosis factor- (TNF-)
Grant Program
AuthorInstitution
Ravi Prakash Rao Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research DIPSAR, New Delhi , India
Ansima Singh Department of Pharmaceutical Science, Birla Institute of Technology, Mesra, Ranchi , India
Arun K Jain Institute of Pathology, Indian Council of Medical Research ICMR, New Delhi , India.
Bhartu Parsharthi Srinivasan Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research DIPSAR, New Delhi , India
Hits: 2620
Download times: 4458
      
Abstract
      Diabetic nephropathy is a major cause of end-stage renal disease (ESRD) in the general population. It is es-timated that diabetic nephropathy will eventually develop in about 40% of all patients with diabetes; therefore, prevention is critical for delaying the development and progression of diabetic kidney disease. Despite extensive efforts, medical advances are still not successful enough to prevent the progression of the disease. In the present study, we focused on the comparison of combination therapies and whether they offered additional renopro-tection. Type 2 diabetes mellitus was induced by intraperitoneally administering streptozotocin (90 mg/kg) in neonatal rats and then these rats were treated with rosiglitazone (1.0 mg/kg) in combination with glimepiride (0.5 mg/kg) or with pioglitazone (2.5 mg/kg) in combination with glimepiride (0.5 mg/kg). Diabetic nephropathy markers were evaluated by biochemical and ELISA kits and renal structural changes were examined by light mi-croscopy and transmission electron microscopy. Results show that the combination of pioglitazone with glimepir-ide is more effective in amelioration of diabetic nephropathy than rosiglitazone with glimepiride drug therapy due to glycemic control, suppressing albumin excretion rate, total protein excretion rate and augmented TNF-a signal-ing during the development of streptozotocin induced type 2 diabetic nephropathy.
Close